Share on StockTwits

Marrone Bio Innovations (NASDAQ:MBII) reached a new 52-week low on Wednesday , Analyst RN reports. The stock traded as low as $3.38 and last traded at $3.45, with a volume of 1,611,114 shares. The stock had previously closed at $5.65.

A number of analysts have recently weighed in on MBII shares. Analysts at Zacks downgraded shares of Marrone Bio Innovations from an “outperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. They now have a $6.60 price target on the stock. Separately, analysts at Robert W. Baird downgraded shares of Marrone Bio Innovations from an “outperform” rating to a “neutral” rating in a research note on Friday, August 8th. They now have a $12.00 price target on the stock, down previously from $15.00. Finally, analysts at Piper Jaffray downgraded shares of Marrone Bio Innovations from an “overweight” rating to a “neutral” rating in a research note on Friday, August 8th. They now have a $11.00 price target on the stock, down previously from $19.00. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Marrone Bio Innovations presently has a consensus rating of “Hold” and an average target price of $13.32.

The stock’s 50-day moving average is $7.6 and its 200-day moving average is $11.04. The company’s market cap is $76.9 million.

Marrone Bio Innovations (NASDAQ:MBII) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.50) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.47) by $0.03. Analysts expect that Marrone Bio Innovations will post $-1.77 EPS for the current fiscal year.

Marrone Bio Innovations, Inc is a provider of bio-based pest management and plant health products. Bio-based products are consists of naturally occurring microorganisms, such as bacteria and fungi, and plant extracts.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.